We used National Surveillance, Epidemiology and End Results (SEER)—Medicare linked data in the United States to evaluate the role of SGLT2 inhibitor initiation on the survival of HCC patients. This evidence concerns the gene SLC5A2 and hepatocellular carcinoma.